Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study

Abstract: We aim to evaluate the efficacy of brentuximab vedotin (BV) combined with gemcitabine (GBV) followed by BV maintenance in relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL). Patients with at least 5% CD30+ cells by immunohistochemistry received 4 GBV induction (28 days) cycles...

Cijeli opis

Bibliografski detalji

Glavni autori:	Olivier Tournilhac, Kamal Bouabdallah, Solène Lecolant, Maya Hacini, Kamel Laribi, Sébastien Bailly, Thibaut Belmondo, Marie Maerevoet, Loic Ysebaert, Stéphanie Guidez, Steven Le Gouill, Christophe Bonnet, Marc André, Jehan Dupuis, Catherine Thieblemont, Emmanuel Bachy, Nicolas Daguindau, Franck Morschhauser, Sabine Tricot, Charline Moulin, Anne Banos, Roch Houot, Adrien Chauchet, Emmanuel Gyan, Guillaume Cartron, Hassan Farhat, Vincent Camus, Bernard Drenou, Hacene Zerazhi, David Sibon, Emmanuelle Nicolas-Virelizier, Caroline Delette, Sylvia Snauwaert, Sarah Bailly, Richard Delarue, Sylvain Carras, Albane Ledoux-Pilon, Marie-Cécile Parrens, Samuel Griolet, Philippe Gaulard, Marie-Hélène Delfau-Larue, Laurence de Leval, Gandhi Laurent Damaj
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-12-01
Serija:	Blood Advances
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2473952925004574
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!